The potential of 4D's approach in curbing antimicrobial resistance among bacterial pathogens.

Microbial drug resistance antimicrobial stewardship antimicrobial susceptibility testing dose duration and de-escalation optimal antibiotic therapy right drug

Journal

Expert review of anti-infective therapy
ISSN: 1744-8336
Titre abrégé: Expert Rev Anti Infect Ther
Pays: England
ID NLM: 101181284

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 14 9 2022
medline: 26 10 2022
entrez: 13 9 2022
Statut: ppublish

Résumé

Antibiotics are life-saving drugs but irrational/inappropriate use leads to the emergence of antibiotic-resistant bacterial superbugs, making their treatment extremely challenging. Increasing antimicrobial resistance (AMR) among bacterial pathogens is becoming a serious public health concern globally. If ignorance persists, there would not be any antibiotics available to treat even a common bacterial infection in future. This article intends to collate and discuss the potential of 4D's (right More efforts are needed for developing diagnostics for rapid, accurate, point-of-care, and cost-effective pathogen identification and antimicrobial susceptibility testing (AST) to facilitate rational use of antibiotics. Current dosing and duration of therapies also need to be redefined to maximize their impact. Furthermore, de-escalation approaches should be developed and encouraged in the clinic. This altogether will minimize selection pressure on the pathogens and reduce emergence of AMR.

Identifiants

pubmed: 36098225
doi: 10.1080/14787210.2022.2124968
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1401-1412

Auteurs

Lovnish Thakur (L)

Translational Health Science and Technology Institute, Ncr Biotech Science Cluster, Faridabad, India.
Jawaharlal Nehru University, Delhi, India.

Sevaram Singh (S)

Translational Health Science and Technology Institute, Ncr Biotech Science Cluster, Faridabad, India.
Jawaharlal Nehru University, Delhi, India.

Rita Singh (R)

Translational Health Science and Technology Institute, Ncr Biotech Science Cluster, Faridabad, India.
Jawaharlal Nehru University, Delhi, India.

Ashok Kumar (A)

Translational Health Science and Technology Institute, Ncr Biotech Science Cluster, Faridabad, India.

Archana Angrup (A)

Department of Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Niraj Kumar (N)

Translational Health Science and Technology Institute, Ncr Biotech Science Cluster, Faridabad, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH